Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
•
Medical Oncology
•
General Internal Medicine
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Related Questions
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
What are your top takeaways in thoracic cancers from ESMO 2025?
Do you prescribe respiratory muscle training (RMT) devices to patients with dysphagia?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
